IMMEDIATE Therapeutics

Clinical stage co. with a safe & effective therapeutic to reduce heart muscle damage & prevent cardiac arrest in ACS, the most common cause of death & morbidity

  • Stage Full Product Ready
  • Industry Biotechnology
  • Location Boston, MA, USA
  • Currency USD
  • Founded July 2020
  • Employees 5
  • Incorporation Type C-corp
  • Website immtx.com

Company Summary

Aim to establish IMT-358 as the First- & Best-in-class first line therapy providing metabolic protection to minimize cardiac damage & instability during acute coronary syndromes. In our Ph. 2, IMT-358 was administered during ACS in patients seen by EMS following a 911 call. Trial showed IMT-358 reduced cardiac arrest & mortality by 50% & infarct size by 80%. FDA have granted us a SPA for our proposed IMMEDIATE-2 Trial, Breakthrough Therapy & BLA

Team

Starting a startup?

Join the world's largest startup network for guidance, tools, and fundraising opportunities.

Get Started for Free